Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Reprod Toxicol ; 96: 114-127, 2020 09.
Artigo em Inglês | MEDLINE | ID: mdl-32553615

RESUMO

Knowledge on mode-of-action (MOA) is required to understand toxicological effects of compounds, notably in the context of risk assessment of mixtures. Such information is generally scarce, and often complicated by the existence of multiple MOAs per compound. Here, MOAs related to developmental craniofacial malformations were derived from literature, and assembled in a MOA network. A selection of gene expression markers was based on these MOAs. Next, these markers were verified by qPCR in zebrafish embryos, after exposure to reference compounds. These were: triazoles for inhibition of retinoic acid (RA) metabolism, AM580 and CD3254 for selective activation of respectively RA-receptor (RAR) and retinoid-X-receptor (RXR), dithiocarbamates for inhibition of lysyl oxidase, TCDD for activation of the aryl-hydrocarbon-receptor (AhR), VPA for inhibition of histone deacetylase (HDAC), and PFOS for activation of peroxisome proliferator-activated receptor-alpha (PPARα). Next, marker gene profiles for these reference compounds were used to map the profiles of test compounds to known MOAs. In this way, 2,4-dinitrophenol matched with the TCDD and RAR profiles, boric acid with RAR, endosulfan with PFOS, fenpropimorph with dithiocarbamates, PCB126 with AhR, and RA with triazoles and RAR profiles. Prochloraz showed no match. Activities of these compounds in ToxCast assays, and in silico analysis of binding affinity to the respective targets showed limited concordance with the marker gene expression profiles, but still confirmed the complex MOA profiles of reference and test compounds. Ultimately, this approach could be used to support modeling of mixture effects based on upfront knowledge of (dis)similarity of MOAs.


Assuntos
Anormalidades Craniofaciais/induzido quimicamente , Regulação da Expressão Gênica no Desenvolvimento/efeitos dos fármacos , Teratogênicos/toxicidade , Animais , Anormalidades Craniofaciais/genética , Relação Dose-Resposta a Droga , Embrião não Mamífero , Feminino , Masculino , Modelos Biológicos , Teratogênicos/classificação , Peixe-Zebra
2.
Food Chem Toxicol ; 137: 111117, 2020 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-31927004

RESUMO

A challenge in cumulative risk assessment is to model hazard of mixtures. EFSA proposed to only combine chemicals linked to a defined endpoint, in so-called cumulative assessment groups, and use the dose-addition model as a default to predict combined effects. We investigated the effect of binary mixtures of compounds known to cause craniofacial malformations, by assessing the effect in the head skeleton (M-PQ angle) in 120hpf zebrafish embryos. We combined chemicals with similar mode of action (MOA), i.e. the triazoles cyproconazole, triadimefon and flusilazole; next, reference compounds cyproconazole or triadimefon were combined with dissimilar acting compounds, TCDD, thiram, VPA, prochloraz, fenpropimorph, PFOS, or endosulfan. These mixtures were designed as (near) equipotent combinations of the contributing compounds, in a range of cumulative concentrations. Dose-addition was assessed by evaluation of the overlap of responses of each of the 14 tested binary mixtures with those of the single compounds. All 10 test compounds induced an increase of the M-PQ angle, with varying potency and specificity. Mixture responses as predicted by dose-addition did not deviate from the observed responses, supporting dose-addition as a valid assumption for mixture risk assessment. Importantly, dose-addition was found irrespective of MOA of contributing chemicals.


Assuntos
Anormalidades Craniofaciais/veterinária , Doenças dos Peixes/etiologia , Silanos/toxicidade , Triazóis/toxicidade , Peixe-Zebra/embriologia , Animais , Anormalidades Craniofaciais/embriologia , Anormalidades Craniofaciais/etiologia , Doenças dos Peixes/embriologia , Peixe-Zebra/anormalidades , Peixe-Zebra/genética
3.
Food Chem Toxicol ; 113: 134-144, 2018 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-29374592

RESUMO

Aflatoxin B1 (AfB1) is a secondary fungal metabolite product widely found in many foodstuffs and considered a public health concern worldwide due to its genotoxicity and carcinogenicity. Tropical climate and inappropriate food safety practices in Indonesia are the favorable conditions for AfB1 contamination of foodstuffs. Despite these challenges, there has been a limited number of risk assessment of AfB1 conducted in Indonesia. Therefore, this paper aimed to gather all available occurrence data of AfB1 in maize and peanut originating from Indonesia and used the occurrence data to evaluate the risk of exposure to AfB1 using the Margin of Exposure (MOE) and the quantitative liver cancer risk approaches established by EFSA and FAO/WHO respectively. Risk assessment using both the MOE and quantitative liver cancer risk approaches revealed that AfB1 exposure from maize and peanut consumption in Indonesia is of concern. The MOE values derived from consumption of maize and peanut originating from Indonesia were generally below 10,000, and for several occurrence data were even below 1000. The estimated number of liver cancer cases associated with AfB1 exposure generally was above the 0.1 cancer cases/100,000 individuals/75 years. Altogether the evaluation reveals the urgency for risk management of AfB1 in Indonesia.


Assuntos
Aflatoxina B1/toxicidade , Arachis/química , Exposição Dietética , Neoplasias Hepáticas/epidemiologia , Zea mays/química , Humanos , Indonésia/epidemiologia , Neoplasias Hepáticas/induzido quimicamente , Nível de Efeito Adverso não Observado , Medição de Risco/métodos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...